An observational study in Sickle Cell Disease, Thalassemia, Beta and Thalassemia Alpha, sponsored by Cyprus Institute of Neurology and Genetics. Recruiting at 26 sites in 16 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-03-20.
Sponsored by Cyprus Institute of Neurology and Genetics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Hemoglobinopathies, including sickle cell disease (SCD) and beta-thalassemia, are prevalent diseases with variable clinical manifestation and severity that are thought to be governed, in part, by genetic modifiers. Despite the identification and characterization of a few putative genetic modifiers by previous studies, these are as yet insufficient to guide treatment recommendations or risk-stratify patients reliably. Also, it is expected that many additional genetic variants exist that can modify disease and its severity. This large-scale genome-wide association study (GWAS) will utilize SNP chips to investigate the genetic profile of individuals with hemoglobinopathies, thereby addressing the challenges of previous studies related to small sample sizes and low statistical power, while promoting the participation of diverse populations worldwide. The study aims to i) discover new genetic modifiers of hemoglobinopathies, ii) validate previously reported genetic modifiers, iii) pool and analyze existing genomic data, iv) standardize phenotypic descriptions, v) develop a research resource of disease-specific data generated in INHERENT, including genomic, phenotypic, and functional data, and vi) develop risk scores that can be used for patient stratification.
The main endpoints include:
Genetic modifiers affecting clinical or laboratory phenotypes of hemoglobinopathies, including
Genetic modifiers affecting response to treatment, including
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
This study's planned enrollment of 30,000 is above the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.
Browse Anemia, Sickle Cell studies →This is the only study on the registry with Cyprus Institute of Neurology and Genetics as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Individuals diagnosed with an inherited hemoglobinopathy and are under regular follow-up in the participating centers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals with hemoglobinopathies
Genetic: GWAS
The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
Genetic modifiers in haemoglobinopathies through GWAS
Number of genetic variants (SNPs) associated with disease-specific phenotypes
Time frame: 5 years
Started Oct 2022 (actual). Primary completion is estimated for Sep 2027, 59 months after the start.
Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 59 months is above that.
Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.